344 related articles for article (PubMed ID: 31431473)
1. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
[TBL] [Abstract][Full Text] [Related]
2. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
3. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
[TBL] [Abstract][Full Text] [Related]
4. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
McCarty MF; Hejazi J; Rastmanesh R
Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
[TBL] [Abstract][Full Text] [Related]
5. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
6. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
[TBL] [Abstract][Full Text] [Related]
7. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
8. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
9. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
10. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
[TBL] [Abstract][Full Text] [Related]
11. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
12. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
13. Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer.
Yu J; Zhou P; Du W; Xu R; Yan G; Deng Y; Li X; Chen Y
Biochem Pharmacol; 2020 Jul; 177():113946. PubMed ID: 32247852
[TBL] [Abstract][Full Text] [Related]
14. Androgens in prostate cancer: A tale that never ends.
Hou Z; Huang S; Li Z
Cancer Lett; 2021 Sep; 516():1-12. PubMed ID: 34052327
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
18. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
Gustafson JL; Neklesa TK; Cox CS; Roth AG; Buckley DL; Tae HS; Sundberg TB; Stagg DB; Hines J; McDonnell DP; Norris JD; Crews CM
Angew Chem Int Ed Engl; 2015 Aug; 54(33):9659-62. PubMed ID: 26083457
[TBL] [Abstract][Full Text] [Related]
19. ASC-J9
Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
[TBL] [Abstract][Full Text] [Related]
20. High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor.
Dellal H; Boulahtouf A; Alaterre E; Cuenant A; Grimaldi M; Bourguet W; Gongora C; Balaguer P; Pourquier P
Cells; 2020 Jun; 9(6):. PubMed ID: 32560058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
